

- tients with pulmonary embolism. *N Engl J Med* 1980; 303: 842-5
152. Sharma GVRK, Folland ED, McIntyre KM, et al. Longterm hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease [abstract]. *J Am Coll Cardiol* 1990; 15: 65A
 153. Urokinase-Streptokinase Embolism Trial: phase 2 results. *JAMA* 1974; 229: 1606-13
 154. UKEP Study Research Group. The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. *Eur Heart J* 1987; 8: 2-10
 155. Verstraete M, Miller GAH, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. *Circulation* 1988; 77: 353-60
 156. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicentre trial. *J Am Coll Cardiol* 1992; 20: 24-30
 157. Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism. *Chest* 1992; 101 Suppl. 4: 183S-5S
 158. Goldhaber SZ. Pulmonary embolism thrombolysis: a clarion call for international collaboration. *J Am Coll Cardiol* 1992; 19: 246-7
 159. King JN, Champlin AM, Ashby RN. Vena cava filters. *West J Med* 1992; 156: 295-6
 160. Grassi CJ. Inferior vena caval filters: analysis of five currently available devices. *AJR - Am J Roent* 1991; 156: 813-21
 161. Thery C, Asseman P, Amrouni N, et al. Use of a new removable vena cava filter in order to prevent pulmonary embolism in patients submitted to thrombolysis. *Eur Heart J* 1990; 11: 334-41
 162. Greenfield LJ. Evolution of venous interruption for pulmonary thromboembolism. *Arch Surg* 1992; 127: 622-6
 163. Ballew KA, Philbrick JT, Becker DM. Vena cava filter devices. *Clin Chest Med* 1995; 16 (2): 295-305

Correspondence and reprints: Dr G.F. Pineo, F6-841 Centre Avenue East, Calgary, Alberta, T2E 0A1, Canada.

Errata

Vol. 51, No. 1, page 38: In the first sentence of section 4.1, the mortality figures at 1 year in parentheses should read: '73% treated versus 35% placebo'.

In the last paragraph of section 4.1, the review time by the US FDA should read: '. . . only 6 months after original submission'.

[Festoff BW. *Amyotrophic lateral sclerosis: current and future treatment strategies. Drugs* 1996 Jan; 51 (1): 28-44]

Vol. 51, No. 3, page 463: In the last paragraph, the figures in parentheses in the second sentence should read: '(61 to 83% vs 35 to 67% at 2 weeks; 92 to 100% vs 75 to 97% at 4 weeks)'.

[Fitton A, Wiseman L. *Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs* 1996 Mar; 51 (3): 460-482]